Loading...
•
Sep 30, 2021
Tempest Q3 2021 Earnings Report
Tempest Therapeutics reported financial results for the third quarter ended September 30, 2021.
Key Takeaways
Tempest Therapeutics reported a net loss of $8.1 million, or $1.21 per share, for the third quarter of 2021. The company ended the quarter with $59.8 million in cash and cash equivalents. Research and development expenses were $4.6 million, and general and administrative expenses were $3.1 million.
Dosed first patients in first line, randomized, global Phase 1b/2 hepatocellular carcinoma (HCC) study of TPST-1120 combination regimen, in collaboration with F. Hoffmann La Roche.
In-licensed exclusive rights to novel oncology target from the lab of Russell Vance, Ph.D., at the University of California at Berkeley (U.C. Berkeley).
Continued enrollment in TPST-1495 monotherapy dose optimization towards recommended Phase 2 dose.
Commenced first line, randomized global Phase 1b/2 study in HCC patients, under a collaboration with F. Hoffmann La Roche for TPST-1120.
Forward Guidance
Tempest expects to have sufficient resources to fund operations into the second quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...